NCT03258333 is a clinical trial of aortic valve replacement in Aortic Valve Replacement, sponsored by The Federal Centre of Cardiovascular Surgery, Russia.

Who is sponsoring NCT03258333?

NCT03258333 is sponsored by The Federal Centre of Cardiovascular Surgery, Russia.

What drugs are being tested in NCT03258333?

Interventions in NCT03258333: aortic valve replacement.

What condition does NCT03258333 study?

NCT03258333 studies Aortic Valve Replacement.

Is NCT03258333 still recruiting?

NCT03258333 is currently status unknown. Last updated 23 August 2017.

Last reviewed 2017-08-23 · How we verify

NCT03258333

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Small Aortic Annulus - a New Solution to the Old Problem

Status unknown Last updated 23 August 2017

What this trial tests

trial testing aortic valve replacement in Aortic Valve Replacement in 60 participants. Status unknown.

Timeline

18 February 2017

Primary endpoint
1 January 2022

1 July 2022

Quick facts

Lead sponsor	The Federal Centre of Cardiovascular Surgery, Russia
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	60
Start date	18 February 2017
Primary completion	1 January 2022
Estimated completion	1 July 2022
Sites	1 location across Russia

Drugs / interventions tested

aortic valve replacement

Conditions studied

Aortic Valve Replacement — all drugs for Aortic Valve Replacement →

Sponsor

The Federal Centre of Cardiovascular Surgery, Russia

Who can join

Adults 60 to 90, any sex, with Aortic Valve Replacement. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective single-center study included 60 patients with a severe degenerative aortic stenosis and small aortic annulus (\<21 mm) who underwent standard AVR with stented bioprosthesis (group 1, n=30) and aortic valve reconstruction using autologus pericardium (Ozaki procedure) (group 2, n=30)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of aortic valve replacement

Trials testing the same drug.

NCT03667365 — Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Pr · NA · terminated
NCT03976817 — Aortic Valve Replacement Above the Aortic Annulus (SA-AVR) With the Carpentier-Edwards Magna-Ease Bioprosthesis · completed

Other recruiting trials for Aortic Valve Replacement

Currently open trials in the same condition.

NCT07123480 — The Role of 4 Different Consent Approaches on a Pilot Study to Increase Cardiac Rehabilitation Attendance · NA · active not recruiting
NCT05295628 — Evaluation of Safety and Effectiveness of the EMBLOK EPS During TAVR · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03258333 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Federal Centre of Cardiovascular Surgery, Russia
Last refreshed: 23 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03258333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing